GSK, XenoPort receive complete response letter for RLS drug

LONDON The Food and Drug Administration has declined to approve a drug used to treat restless leg syndrome, the drug’s makers announced Wednesday.

GlaxoSmithKline and XenoPort said they had received a complete response letter for the FDA for their application for Horizant (gabapentin enacarbil) extended-release tablets submitted in January 2009. A complete response letter means that the FDA has reviewed an approval application, but questions remain that preclude its approval.

The FDA cited a finding of tumors found in the pancreas cells of rats during preclinical testing as a sufficient concern to preclude the drug’s approval. While similar problems were found when the agency approved the drug as a treatment for refractory epilepsy, it said Horizant’s benefits for refractory epilepsy patients justified the potential risks. GSK and XenoPort have said they are evaluating the letter.

Login or Register to post a comment.